Regenxbio Inc RGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
-
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
-
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
-
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
-
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
-
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
Trading Information
- Previous Close Price
- $8.09
- Day Range
- $7.95–8.28
- 52-Week Range
- $5.46–16.19
- Bid/Ask
- $8.01 / $8.28
- Shares Outstanding
- 66.01M
- Market Cap
- $532.73M
- Volume/Avg
- 859,286 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 371
- Website
- https://www.regenxbio.com
Valuation
|
Metric
|
RGNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.09 |
Price/Sales | 2.41 |
Price/Cash Flow | — |
Price/Earnings
RGNX
Financial Strength
|
Metric
|
RGNX
|
|---|---|
Quick Ratio | 2.57 |
Current Ratio | 2.86 |
Interest Coverage | −3.68 |
Quick Ratio
RGNX
Profitability
|
Metric
|
RGNX
|
|---|---|
Return on Assets (Normalized) | −35.29% |
Return on Equity (Normalized) | −141.46% |
Return on Invested Capital (Normalized) | −63.72% |
Return on Assets
RGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$sJsMT | LOCK|&CFfz | $129B | |||
| Moderna Inc
MRNA
| LOCK|dsqphZ | LOCK|@L | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sx#>&^ | LOCK|RPVNv | $77B | |||
| argenx SE ADR
ARGX
| LOCK|lDF^$r | LOCK|pCb | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r#ph@W | LOCK|@x | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@vC^H# | LOCK|b!Z$% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|n?^%ZJtr | LOCK|vM>$y | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@!p?t$@ | LOCK|@pK | $24B | |||
| Incyte Corp
INCY
| LOCK|%^Vy^B! | LOCK|!j | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^xBP^$! | LOCK|kn | $14B |
United States